Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.71% to $490.47 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2. ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...